Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis
AS Halling, N Loft, JI Silverberg… - Journal of the American …, 2021 - Elsevier
Background Dupilumab, the first biological drug to be approved for the treatment of
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …
moderate to severe atopic dermatitis in adolescents and adults, has shown good efficacy …
Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis
Background Management of moderate-to-severe atopic dermatitis (AD) commonly requires
long-term treatment. Objective The aim of this study was to report the safety and efficacy of …
long-term treatment. Objective The aim of this study was to report the safety and efficacy of …
Real‐world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records
C Wang, CN Kraus, KG Patel… - International Journal …, 2020 - Wiley Online Library
Background Clinical trial data for dupilumab, a monoclonal antibody against the interleukin‐
4 receptor (IL‐4Rα), have shown that it is safe and effective for the treatment of moderate to …
4 receptor (IL‐4Rα), have shown that it is safe and effective for the treatment of moderate to …
[HTML][HTML] Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials …
Background Two phase 3 trials with identical design, LIBERTY AD SOLO 1 (NCT02277743)
and LIBERTY AD SOLO 2 (NCT02277769), confirmed dupilumab efficacy and safety versus …
and LIBERTY AD SOLO 2 (NCT02277769), confirmed dupilumab efficacy and safety versus …
Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial
M Worm, EL Simpson, D Thaçi, R Bissonnette… - JAMA …, 2020 - jamanetwork.com
Importance The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled,
moderate to severe atopic dermatitis (AD). Objective To assess the efficacy and safety of …
moderate to severe atopic dermatitis (AD). Objective To assess the efficacy and safety of …
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay …
LFM Ariëns, J van der Schaft, LS Spekhorst… - Journal of the American …, 2021 - Elsevier
Background Real-life data on long-term effectiveness and safety of dupilumab in atopic
dermatitis patients are limited. Objective To study 52-week effectiveness and safety of …
dermatitis patients are limited. Objective To study 52-week effectiveness and safety of …
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
S Faiz, J Giovannelli, C Podevin, M Jachiet… - Journal of the American …, 2019 - Elsevier
Background Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its
effectiveness and safety were demonstrated in clinical trials. Objective We sought to assess …
effectiveness and safety were demonstrated in clinical trials. Objective We sought to assess …
[HTML][HTML] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Background Significant unmet need exists for long-term treatment of moderate to severe
atopic dermatitis (AD). Objective To assess the long-term safety and efficacy of dupilumab in …
atopic dermatitis (AD). Objective To assess the long-term safety and efficacy of dupilumab in …
[HTML][HTML] Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the …
AL Bosma, LEM de Wijs, MH Hof… - Journal of the American …, 2020 - Elsevier
Background Evidence on long-term dupilumab treatment for atopic dermatitis in daily
practice is lacking. Objective To investigate patient characteristics, treatment aspects …
practice is lacking. Objective To investigate patient characteristics, treatment aspects …
Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis
LA Beck, M Deleuran, R Bissonnette… - American journal of …, 2022 - Springer
Background Moderate‐to‐severe atopic dermatitis (AD) often requires long-term
management with systemic therapies. Objective Our objective was to report the safety and …
management with systemic therapies. Objective Our objective was to report the safety and …